Quick Answer
BioCardia, Inc. reported Cash and Equivalents of $2.50 million for fiscal year 2025.
BioCardia, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $2.50M | +5.3% |
| 2024 | $2.37M | +115.0% |
| 2023 | $1.10M | -85.0% |
| 2022 | $7.36M | -42.8% |
| 2021 | $12.87M | -39.9% |
| 2020 | $21.41M | +283.3% |
| 2019 | $5.58M | +4.2% |
| 2018 | $5.36M | -57.8% |
| 2017 | $12.69M | -40.6% |
| 2016 | $21.35M | -11.0% |
| 2016 | $24.00M | +574.7% |
| 2015 | $3.56M | +11.7% |
| 2014 | $3.18M | -76.1% |
| 2013 | $13.29M | +0.2% |
| 2012 | $13.27M | +3.5% |
| 2012 | $12.82M | +1.1% |
| 2011 | $12.68M | +9882.7% |
| 2010 | $127.0K | -97.4% |
| 2009 | $4.97M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.29M | +7.2% | +439.5% |
| June 30, 2025 | $980.0K | -31.0% | +3.3% |
| March 31, 2025 | $949.0K | +0.0% | -60.0% |
| December 31, 2024 | $2.37M | +115.0% | -51.9% |
| September 30, 2024 | $4.93M | +168.7% | +246.9% |
| June 30, 2024 | $1.42M | -67.0% | +49.7% |
| March 31, 2024 | $949.0K | -80.5% | -14.0% |
| December 31, 2023 | $1.10M | -85.0% | -39.9% |
- BioCardia, Inc. showed an increase of +5.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2025 period, BioCardia, Inc.’s cash and equivalents has declined by 49.8% (from $4.97 million to $2.50 million).
- The most recent figure is from BioCardia, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: